Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Albert Pavalonis

Vascular Surgery Lynchburg, VA Doctor of Osteopathy

NPI 1326302563 CMS profile 5148759

2410 Atherholt Rd, Lynchburg, VA 24501

Open in the dashboard

General payments

$31,684

229 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Albert Pavalonis of Lynchburg, VA is reported in the CMS Open Payments database as having received $31,684 across 229 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,488 48
2024 General $1,381 25
2023 General $4,448 34
2022 General $3,957 28
2021 General $1,009 27
2020 General $1,000 23
2019 General $5,401 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Albert Pavalonis
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Albert Pavalonis were reported at $14,488. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Albert Pavalonis Vascular Surgery median Middle half National median
2019 $5,401 $796 $226–$2,363 $163
2020 $1,000 $348 $118–$1,110 $114
2021 $1,009 $471 $158–$1,421 $132
2022 $3,957 $725 $222–$2,183 $149
2023 $4,448 $836 $257–$2,440 $160
2024 $1,381 $909 $252–$2,619 $164
2025 $14,488 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $16,433 80 payments
  2. Medtronic Vascular, Inc. $4,858 57 payments
  3. Silk Road Medical, Inc. $4,353 23 payments
  4. Penumbra, Inc. $3,269 12 payments
  5. Abbott Laboratories $1,082 15 payments
  6. Bard Peripheral Vascular, Inc. $695 15 payments
  7. Medical Device Business Services, Inc. $261 2 payments
  8. Cook Medical LLC $173 10 payments
  9. Inspire Medical Systems, Inc. $145 2 payments
  10. CVRx, Inc. $129 3 payments
  11. Other $286 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $19,032 27 payments
  2. Food and Beverage $10,518 199 payments
  3. Consulting Fee $1,950 1 payment
  4. Education $184 2 payments
Products named General payments · program years 2019–2025
  1. ENDURANT IIS $14,205 38 payments
  2. Indigo System $3,237 10 payments
  3. ENROUTE Transcarotid Stent $2,941 15 payments
  4. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $2,941 15 payments
  5. Endurant $2,703 40 payments
  6. Valiant Navion $2,114 15 payments
  7. ENROUTE 0.014 Guidewire $1,412 8 payments
  8. ENROUTE Transcarotid Stent System $1,412 8 payments
  9. ENROUTE Transcarotid Neuroprotection System Carotid Artery Disease $1,412 8 payments
  10. ENHANCE Transcarotid Peripheral Access Kit $1,412 8 payments
  11. Other $5,440 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

175

Median for Vascular Surgery: 122

Drug cost

$37,867

Median for Vascular Surgery: $14,135

Branded share of claims

65.7%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 29 $18,940
Xarelto Rivaroxaban Brand 12 $17,461
Cilostazol Generic 41 $684
Clopidogrel Clopidogrel Bisulfate Brand 56 $454
Atorvastatin Calcium Generic 19 $180
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 18 $149

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 115 billing codes

Paid by Medicare

$139,435

Medicare's payments for the services billed

Medicare patients

274

Average age 76

Services billed

690

122 women, 152 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 56%
Arthritis 50%
Ischemic heart disease 48%
Diabetes 47%
Heart failure 37%
Atrial fibrillation 34%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

229 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record